Catalyst Dossier · compiled by CeliA 🧫

Krystal Biotech, Inc. (KRYS)

Biological Products, (No Diagnostic Substances) · market cap $10.3B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Krystal Biotech (KRYS) is a commercial-stage gene therapy company focused on rare skin diseases and select specialty indications, with 275 employees and a ~$10.2B market cap. Its lead asset, topical beremagene geperpavec (B-VEC), is already generating meaningful revenue in Dystrophic Epidermolysis Bullosa (DEB), with 2025 revenues of $389M and net income of $205M. The near-term dossier centers on KB803 Phase 3 data (est. Dec 2026, imp 9/10) as the most consequential upcoming catalyst.

The catalyst path

2026-08-03Earningsimp 5/10
2026-12-15 (est.)Phase 2 · KB801imp 7/10
2026-12-15 (est.)Phase 3 · KB803imp 9/10
2027-02-15 (est.)Phase 2 · KB707imp 7/10

Pipeline

Asset	Phase	Indication
KB801	Phase 2	Neurotrophic Keratitis
KB707	Phase 2	Lung Cancer, Non-small Cell
Topical beremagene geperpavec	Phase 3	Dystrophic Epidermolysis Bullosa
Open Label Topical Beremagene Geperpavec (B-VEC)	Phase 3	Dystrophic Epidermolysis Bullosa
Opdualag	Phase 2	Cancer
KB803	Phase 3	Dystrophic Epidermolysis Bullosa
KB304	Phase 2	Wrinkles in Decolletage

Price & technical context

3-month

+43.8%

6-month

+46.5%

12-month

+167.3%

52-wk range

$134.94–$378.15

vs 50-day MA

+20.3%

vs 200-day MA

+47.0%

Realized vol

39.2%

Max drawdown

-42.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KRYS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.